{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-121296","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2025-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.309340+00:00","generated_at":"2026-05-21T02:45:09.489388+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin acquires Inozyme for $4.00/share (~$270M cash); adds late-stage ENPP1 therapy","bullets":["All-cash tender offer at $4.00 per share; total equity value ~$270M; expected to close Q3 2025.","INOZYME's lead asset INZ-701 is a Phase 3 enzyme replacement for ENPP1 Deficiency; first pivotal data in children expected early 2026.","Inozyme Board unanimously recommends; stockholders representing ~11.2% of shares have entered support agreements.","BioMarin reaffirms FY2025 guidance and plan to achieve 40% Non-GAAP Operating Margin in 2026.","Transaction not subject to financing condition; Goldman Sachs advised BioMarin, Centerview advised Inozyme."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-121296","json":"https://secwatch.observer/filing/0001193125-25-121296.json","markdown":"https://secwatch.observer/filing/0001193125-25-121296.md","text":"https://secwatch.observer/filing/0001193125-25-121296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312525121296/0001193125-25-121296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312525121296/d833625d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T02:45:09.489388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}